Analysts Review Bausch Health and Sanofi
Recent assessments from analysts indicate a neutral stance on Bausch Health Companies (BHC) and Sanofi (SNYNF), suggesting no clear bullish or bearish sentiment toward these stocks.
Bausch Health Companies (BHC)
TD Cowen’s analyst Michael Nedelcovych has maintained a Hold rating on Bausch Health, recently setting a price target of $7.00. The stock closed last Friday at $5.71.
Nedelcovych currently holds a ranking of 0 stars on TipRanks.com, which operates on a scale of 0-5 stars, with an average return of -15.8% and a 27.9% success rate. His analysis focuses on the healthcare sector and includes companies like Takeda Pharmaceutical Company, Molecular Partners AG, and Coherus Biosciences.
The consensus among analysts for Bausch Health remains a Hold, with an average price target of $8.33, which reflects a potential upside of 44.1% from the current share price. On July 25, Truist Financial also issued a Hold rating with a price target of $6.78.
Sanofi (SNYNF)
For Sanofi, Kepler Capital analyst Nicolas Pauillac reiterated a Hold rating on July 31, establishing a price target of EUR95.00. The stock was priced at $92.56 last Friday, close to its 52-week low of $88.90.
Pauillac ranks #974 out of a total of 9,914 analysts on TipRanks.com.
The broader analyst consensus for Sanofi is categorized as a Moderate Buy, with an average price target of $127.69, indicating a potential upside of 38.0%. Additionally, a report from Deutsche Bank on July 17 also supported a Hold rating with a EUR100.00 price target.
